All In Biotech

Drug Trial Radar · NCT06834230

Effect of Dotinurad in Hyperuricemia With Hypertension

Effect of Dotinurad in Hyperuricemia With Hypertension: a Randomized Study With Febuxostat (DIANA-NEXT)

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Jul 31, 2027

Study completion Mar 31, 2030

Sponsor

Lead sponsor
Saga UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The effect of dotinurad on CAVI (cardio-ankle vascular index) will be compared with that of febuxostat in patients with hyperuricemia complicated by hypertension.

Conditions

  • Hyperuricemia or Gout
  • Hypertension

Interventions

  • DotinuradDrug

    Start at 0.5 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (2 mg once daily).

  • FebuxostatDrug

    Start at 10 mg once daily, and then referring to the attached document, gradually increase the dose to the maintenance dose (40 mg once daily).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in CAVITime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saga University

    Saga, Saga-ken, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.